Experience

Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…

Davis Polk advised Mr. David Chow (Co-Chairman and Executive Director of Macau Legend), All Landmark Properties Limited and PacBridge Capital Partners (HK) Limited as the selling…

Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…

Davis Polk advised Ming Yuan Cloud Group Holdings Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk advised the initial purchasers in connection with a $250 million Regulation S only offering by China South City Holdings Limited (“CSC”) of its 10.750% senior notes due 2023…

Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate consideration of approximately HK$1.2 billion (approximately US…

Davis Polk advised the joint lead managers in connection with a $50 million Regulation S offering by Shuifa International Holdings (BVI) Co., Ltd of its 4.300% guaranteed bonds due 2023 to…

Davis Polk advised the initial purchasers in connection with a $200 million Regulation S only offering by China South City Holdings Limited of its 11.500% senior notes due 2021. CSC is a…

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…